Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazole DDI with Repaglinide and Caffeine
NCT02128321Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isavuconazole in invasive aspergillosis (IA) and mucormycosis, sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve from time of dosing to the last quantifiable concentration for Repaglinide at Day 14, Area under the concentration-time curve from time 0 extrapolated to infinity for Repaglinide at Day 14 and 12 more. Started Jan 2014; status: completed.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on NCT02128321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128321.